Yearly zoledronic acid in postmenopausal osteoporosis [3]

New England Journal of Medicine

Volumn 357, Issue 7, 2007, Pages 712-713

  Karam, Roger ^a   Camm, John ^b   McClung, Michael ^c  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 34547944533     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6.
2. Steinbuch M, D'Agostino RB, Mandel JS, et al. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 2002;35:320-6.